article thumbnail

Some action points for the next PM

Express Pharma

Biogenerics comes with higher risks, as the manufacturing process and technologies are more complex. India’s traditional strength lies in small molecule chemical-based drugs which is why not too many companies focus on biologics. The DoP report also points out that biogenerics need different approaches to deal with IP challenges.

article thumbnail

NHC Comments on the Federal Evidence Agenda on Disability Equity

Putting Patients First Blog

Too often the formal notice and comment process does not reach these marginalized communities and federal agencies must actively work to seek their input in non-traditional ways. This process respects their autonomy by involving them in decision-making to the extent that they are able.